Destroying tumors by targeting cancer cell fitness.
Cambridge, MA
Joined December 2022
- Tweets62
- Following29
- Followers33
- Likes10
Announcing the first participant has been dosed in the Ph1 study for LRK-4189, a 1st-in-class targeted protein degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC). Learn more bit.ly/3MePHZR
We’re proud to present new data at #SITC2025. We will share preclinical research on our lead candidate, LRK-4189, which we anticipate advancing into a first-in-human clinical study soon.
Abstract: bit.ly/4hKCh3j #ColorectalCancer @sitcancer
ALT Larkspur at SITC 2025
Don't miss @drughunter_com 's case study of our lead candidate, LRK-4189. ➡️ bit.ly/4pNgHPr
#biotech #cancerresearch #colorectalcancer
LRK-4189: A Potential First-in-Class PIP4K2C Degrader Heads to the Clinic | drughunters.com/474hvrI
PIP4K2C has minimal catalytic activity, but reported scaffolding roles make it well-suited for targeted degradation.
Building on insights from tool inhibitors and an academic degrader, Larkspur optimized a CRBN-recruiting molecule, LRK-4189, now planned for first-in-human study in MSS colorectal cancer.
Ex vivo CRC spheroid responses, supportive once-daily PK/PD, and xenograft proof-of-concept underpin the program.
Read it on Drug Hunter: drughunters.com/474hvrI
While at the #NYSE for a Biotech CEO Sisterhood event, CEO Catherine Sabatos-Peyton discussed our cancer cell fitness approach with @BiotechTV’s @bradloncar.
➡️ Watch the full video at: bit.ly/3I9YoCZ
#Cancer #Biotech #CancerResearch
𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐄𝐎 𝐒𝐢𝐬𝐭𝐞𝐫𝐡𝐨𝐨𝐝 𝐚𝐭 𝐍𝐘𝐒𝐄: Catherine Sabatos-Peyton is leading @LarkspurBio, a company targeting cancer cell fitness.
Full video: biotechtv.com/post/larkspur-…
Thanks to @MaverickNY of Biotech Strategy Blog for her insightful take on why PIP4K2C stands out as a cancer fitness target and how LRK-4189, our 1st-in-class degrader of this lipid kinase, has the potential to treat MSS CRC. #Biotech #Cancer
Time to talk turkey on how protein degradation may be a useful strategy for tackling a dark lipid kinase & overcome acquired resistance in CRC. Nice story from @LarkspurBio
tinyurl.com/ynftnd7y
Announcing the discovery of LRK-4189, a 1st-in-class degrader of the lipid kinase PIP4K2C for the treatment colorectal cancer (CRC).
We presented at the MEDI First Time Disclosures: Breakthroughs on New Medicines session at #ACSFALL2025. bit.ly/4lCSVCm #Cancer
#ACSFall2025 news: we’re presenting on the discovery of LRK-4189, a 1st-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC). @AmerChemSociety Fall Meeting: bit.ly/47dKnOX #CancerResearch
This #NationalCancerResearchMonth, we’re planning for the first clinical trial evaluating our lead candidate & feeling invigorated after sharing data at #AACR. We're proud to be a part of the cancer research community, turning scientific advancements into breakthrough treatments.
Not to be missed from #AACR25: Larkspur presented new preclinical data on two novel programs that disrupt cancer cell fitness. Check out our findings:
✓ Pin 1 degradation bit.ly/431m9mZ
✓ PIP4K2C degradation in #ColorectalCancer bit.ly/4d5dMeY
#CancerResearch
We’re at #AACR25! Don’t miss the newest data on our cancer fitness targeting programs designed to alter the state of cancer cells and ultimately destroy tumors.
Abstracts here:
bit.ly/3FSyh1J
bit.ly/4iJxTRX
#CancerResearch #Cancer
Next month at the @AACR Annual Meeting, we will present new research on our drug candidates targeting key cancer cell fitness genes. Abstracts here: bit.ly/3FSyh1J
bit.ly/4iJxTRX
#AACR25 #CancerResearch
Our CEO, @SabatosPeyton, will join a panel of experts discussing “Accessing Technology to Advance the Pipeline” at the @LongwoodLeaders San Francisco CEO forum on Sunday, Jan. 12. More here: bit.ly/426Q3HU
At Larkspur Bio, we believe in the power of community. We’re grateful to stand with @ls_cares and help make a meaningful impact this holiday season.
Many thanks to our team, which collected contributions for the gift card drive for nonprofit partners. Happy holidays to all!
Larkspur CEO, @SabatosPeyton, will share her perspective on the impact of the #InflationReductionAct on innovation in drug development at a @Lumanity webinar tomorrow. Register at bit.ly/3UK1UH6 #biotech #drugdiscovery
There's still time to register for next week's #InflationReductionAct webinar bringing together perspectives from #patientadvocacy groups and #biotech professionals to discuss the emerging concerns and explore actionable strategies buff.ly/3CeKQTu #IRA #DrugDevelopment
Don’t miss our @sitccancer presentations on key tumor fitness targets:
* new data on our 1st-in-class PIP4K2C protein degrader
* Pin1 degradation as a promising treatment
* how our ML-enabled immune evasion signature models can predict responses to cancer therapy
#SITC2024
#SITC2024: We’re thrilled to share new data on the therapeutic potential of tumor fitness targets PIP4K2C & Pin1.
Our PIP4K2C preclinical study shows that our 1st-in-class protein degrader can specifically target PIP4K2C & reduce tumor growth in CRC patient samples. @sitcancer
Our Pin1 findings and first-in-class degrader program advance understanding of Pin1’s role in fibroblasts AND cancer cells within #cancer.
We will also present how our ML-enabled immune evasion signature models can predict responses to cancer therapies. #cancerresearch #SITC24
We’re excited to share that the @ACSorganic has awarded Larkspur scientist Morgan O’Shea a 2024 Technical Achievement in Organic Chemistry (TAOC) Award. Congrats, Morgan! #MedChem #biotech #ACSFall2024
With today being National Intern Day, we’re pleased to introduce you to our 2024 summer co-ops.
Meet Vishu Agarwal, a sophomore at @cornelluniversity, and Matthew Palmer, a junior at @northeastern. #intern #drugdiscovery #biotech